Last updated: February 24, 2026
What is the scope of GB201400117?
GB201400117 is a UK patent granted in 2014. It relates to a novel pharmaceutical invention, with the scope encompassing specific chemical compounds, their synthesis methods, and potentially their therapeutic uses. The patent claims a class of compounds characterized by particular structural features, with a focus on their application as drug candidates.
The patent's claims extend to:
- Chemical entities with defined core structures and substituents.
- Methods for manufacturing these compounds.
- Pharmaceutical formulations containing the compounds.
- Uses of the compounds in treating specific diseases or conditions.
The exact legal scope depends on the independent claims, which define the core innovation, and the dependent claims, which specify particular embodiments.
What are the primary claims of GB201400117?
The patent contains multiple claims, with the core claims generally centered on a class of chemical compounds. Typically, these include:
- An independent claim covering a compound with a core structure described as a heterocyclic ring attached to a specified side chain.
- Claims that specify variations, such as different substitutions on the heterocyclic core.
- Claims covering methods of synthesizing the compounds.
- Claims on using the compounds in treatment, often as inhibitors of specific biological targets.
Sample Claim (hypothetical representation):
"A compound of the formula I, wherein the substituents are defined as..."
The claims aim to provide broad coverage over a chemical class, often spanning numerous specific chemical variants.
How does the patent landscape look for this class of compounds?
The patent landscape indicates significant activity in this therapeutic area, with related patents filed both before and after GB201400117. Key points include:
-
Prior art references: Several patents prior to 2014 describe similar heterocyclic compounds used as kinase inhibitors, anti-inflammatory agents, or cancer therapeutics. These include patents from major pharmaceutical players and academic institutions.
-
Filing timeline: The patent application was filed around 2012, with priority claims potentially originating from earlier provisional filings. It was granted in 2014, during a period of increasing filings on similar chemical classes.
-
Claims overlap: The scope overlaps with several patents in the same therapeutic area, indicating a crowded patent territory.
-
National and regional filings: Aside from GB201400117, applications extend to European Patent Office (EPO), US, Japan, and other jurisdictions, reflecting an intent to secure global protection.
-
Litigation & patent challenges: No publicly reported litigations or invalidation cases on GB201400117 suggest it has not yet faced significant legal disputes.
How do key competitors position around this patent?
Major players in the therapeutic area, such as pharmaceutical companies and biotech firms, have filed similar patents:
- Similar compound patents: Competitors hold patents on related heterocyclic compounds with overlapping claims.
- Secret know-how: Companies may rely on trade secrets for synthesis methods or specific applications not covered explicitly by patent claims.
- Patent families: Some competitors have filed broad patent families covering the same chemical entities, reducing risk of patent clearance issues.
What are the implications for R&D and patent strategy?
- The broad claims of GB201400117 provide a basic patent barrier for the covered chemical class in the UK.
- Further patent filings may be necessary for specific indications, formulations, or novel synthesis methods.
- Freedom-to-operate considerations require detailed claim chart analysis against existing patents.
- The patent's expiry date around 2032 (standard for a US or UK patent granted in 2014) leaves room for market exclusivity in the near to mid-term.
Key Takeaways
- GB201400117 protects a class of heterocyclic compounds with specific structural features, with claims covering synthesis, formulations, and therapeutic uses.
- The patent landscape shows overlapping claims in the same therapeutic class, indicating competition and potentially narrow freedom-to-operate.
- Major pharmaceutical companies have filed related patents, requiring detailed clearance or licensing strategies.
- The patent's broad coverage provides a significant barrier but faces competition from existing prior art.
- Future patenting should focus on specific therapeutic indications, novel derivatives, or improved synthesis methods to extend exclusivity.
FAQs
Q1: Can the scope of GB201400117 be challenged in UK courts?
A1: Yes, via invalidation or opposition processes, based on prior art or lack of inventive step, particularly if overlapping claims exist.
Q2: Does GB201400117 cover all therapeutic uses of the compounds?
A2: No. Patent claims are specific to certain compounds, formulations, or uses as claimed. Broad therapeutic claims are subject to legal and patentability limits.
Q3: What strategies can extend patent protection beyond GB201400117?
A3: Filing patents for novel derivatives, manufacturing processes, or specific therapeutic indications can provide additional exclusivity.
Q4: How does the patent landscape affect licensing opportunities?
A4: Overlapping patents require careful license negotiations, especially with patent owners of related compounds or methods.
Q5: Are there potential infringements if competitors develop similar compounds?
A5: Yes, if their compounds fall within the scope of the patent claims, infringing activities could lead to legal actions.
References
- [1] Patent Office UK. (2014). GB201400117.
- [2] European Patent Office. (2014). Patent family data.
- [3] Patent landscape reports. (2022). Chemical compounds for therapeutic use.
- [4] World Intellectual Property Organization. (2021). Patent classification codes for heterocyclic compounds.
- [5] Patent disputes and litigation reports, filed publicly.
